Stocks are way too expensive.
The popular, pricey tech names are overheating.
Attention Seniors: MUST-SEE Obscure Social Security Contract
North Korea is incessantly beating its war drums.
Investors are complacent.
Heck, the S&P 500 hasn't posted a 5% pullback in more than a year. Simply put, the bull market is long in the tooth. There's no way around it: conditions are ripe for a hard reset.
Or are they?
I don't have to tell you we're smack in the middle of a seasonal weak spot for stocks. Since 1962, the S&P 500 has posted an average decline of 0.67% in September, Renaissance Macro Research chief Jeff deGraaf notes.
The major averages received this September trading memo. Stocks tanked to begin the short trading week. The Dow Jones Industrial Average dropped more than 225 points, while the Nasdaq Composite shed nearly 1%.
No better time for the herd to start looking for a major market top. Thankfully, we have the latest Barron's cover to set the mood with dazzling perfection...
Here we go again. Everyone's looking to put a fork in the bull.
Let's not forget that stocks survived the threat of an August pullback without flinching. Even factoring in yesterday's soft action, the major averages are perched near their highs. And we're having little trouble finding strong trading setups just below the market's surface.
There are plenty of killer breakouts handing us double-digit gains as we sink our teeth into September trading. Here are three of my favorites:
1. Copper's Cruising
Dr. Copper is back!
It took years. But this little industrial metal that claims to have earned a PhD in economics is taking the market by storm. Most investors didn't believe copper would ever recover from its lows. One look at a long-term chart of the industrial metal reveals a nasty bear market going all the way back to 2011.
But something changed in over the past 10 months...
The post-election rally back in November was the spark that helped copper snap it's nasty downtrend. After seven months of choppy consolidation, copper now sports one of the best-looking breakouts on the market.
Of course, copper's prolonged bear market wasn’t great news for base-metal miners like Freeport-McMoRan Inc. (NYSE: FCX). But thanks to this summer's copper rally, FCX is busting out of the basement and getting back to its old tricks.
I told you FCX could be our ticket to explosive, double-digit gains last month. It's certainly delivered -- and could be ready to stretch its legs again if copper can maintain its momentum this week.
2. Chinese Tech Stays Strong
Chinese tech stocks continue to dominate our trading leaderboard.
Chinese ADRs are stomping all over the gains of your favorite American tech names so far this year. A handful of these stocks are even up triple-digits in 2017. We don't know how long this environment will last. But we can certainly look to bank short-term trading profits as these opportunities materialize.
58.com Inc. (Nasdaq: WUBA), the "Craigslist of China", is up almost 45% since we jumped on shares back in late June. Another one of our Chinese ADR's, Baidu Inc. (Nasdaq: BIDU), is chugging along near its highs (you’re up about 17% since our initial buy). Even after yesterday's pullback, the stock looks ready for the next phase of its breakout.
JD.com (Nasdaq: JD) is our only laggard of the bunch. It's down about 12% since early August. But I'm seeing plenty of buyers stepping in between $40-$42. If we hold these levels, this trade stands a fighting chance...
3. Betting On Biotech
Your biotech trading portfolio is on fire. I liked the looks of the biotech breakout from the very beginning. Now it's finally firing on all cylinders after a couple of minor false starts.
I told you last week that biotech could easily become a market-leading industry during the fourth quarter. The powerful extensions we’re seeing in some of these rallies proves that buyers are getting more confident very day.
You're up nearly 35% on your SPDR S&P Biotech ETF (NYSE: XBI) position since our first entry back in January. Celgene Corp. (Nasdaq: CELG) is showing open gains of more than 11% since our June entry. And Incyte Corp. (Nasdaq: INCY) is back on track (it's sitting right near breakeven for now).
Our last impressive biotech beast, Bluebird Bio Inc. (Nasdaq: BLUE) is already up big since our entry last week. Even after Tuesday's 4% pullback, you're well on your way to booking double-digit gains on the next leg higher...
This article originally appeared on Daily Reckoning.